OMER - オメロス （Omeros Corporation）

Omeros Corporation (OMER) announced Tuesday Phase 1 data for OMS906, its candidate for rare hematological disease paroxysmal nocturnal hemoglobinuria. Read more here.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder. Statistically significant and clinically meaningful improvements were observed in all measured markers of hemolysis, including hemoglobin (Hgb

–Omeros (OMER) said it had been granted $6.69M from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop its lead proprietary PDE7…

https://www.investing.com/news/assorted/omeros-awarded-669-million-grant-from-the-national-institute-on-drug-abuse-for-its-oms527-addiction-program-432SI-3051654

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD). The grant is expected to provide $6.69 million over three years and is intended to support both preclinical cocaine interaction stud

Currently, Omeros Corporation’s (OMER) stock is trading at $4.05, marking a fall of -24.86% from last night’s close. At this price, the stock is -75.15% below its 52-week high of $16.30 and 118.33% above its 52-week low of $1.86. Based on the past 30-day period, the stock price is -41.67% below the high and +14.75% […]

Shares of biopharmaceutical company Omeros Corp. (NASDAQ:OMER) are tanking today after data from its I-SPY COVID-19 trial arm for narsoplimab failed to impress investors. The drug indicated lower mortality risk on its addition to the treatment of critically ill COVID-19 patients. All the patients received standard of care which included dexamethasone and remdesivir. The drug though was not seen to shorten the time to recovery for patients. The data monitoring committee terminated the arm that included narsoplimab before reaching 125 patients and importantly, “Neither the trial’s futility nor graduation criteria had been met in the analysis of the population at the time of termination of the arm.

HeartBeam BEAT +55%. NeuroBo Pharmaceuticals (NRBO) +52%. Shuttle Pharmaceuticals (SHPH) -23%. Omeros OMER -19%.

The shares of commercial-stage biopharma, Omeros Corporation (OMER) fell ~11% in the morning hours Thursday after the company reported data from a clinical trial…

During the last session, Omeros Corporation (NASDAQ:OMER)’s traded shares were 0.53 million, with the beta value of the company hitting 1.16. At the end of the trading day, the stock’s price was $3.82, reflecting an intraday loss of -2.80% or -$0.11. The 52-week high for the OMER share is $16.57, that puts it down -333.77 … We Just Learned Something New About Omeros Corporation (NASDAQ: OMER) This Week With Its -34.92% Loss Read More »

Omeros <> stock rose after the company posted better than-expected Q1 earnings, helped by royalties from ophthalmic product Omidria. Net loss for the quarter was $33M or $0.53…

Gainers Trecora Resources (NYSE: TREC ) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million. Exicure, Inc. (NASDAQ: XCUR ) rose 22.3% to $0.13 after the company reported a $5 million raise in private placement transaction priced at market premium. Purple Innovation, Inc. (NASDAQ: PRPL ) shares jumped 20.7% to $3.7664 after the company reported better-than-expected Q1 EPS and sales results. Endeavour Silver Corp. (NYSE: EXK ) surged 20% to $3.7291 following upbeat quarterly results. Ferroglobe PLC (NASDAQ: GSM ) gained 18.4% to $7.53 after the company reported better-than-expected Q1 EPS results. Celsius Holdings, Inc. (NASDAQ: CELH ) surged 16.4% to $48.10 after the company reported better-than-expected Q1 sales results. H&R Block, Inc. (NYSE: HRB ) gained 16% to $27.55 as the company posted upbeat Q3 results and raised FY22 sales guidance. Callaway Golf Company (NYSE: ELY ) jumped 15.9% to $20.81 after the company reported better-than-expected Q1 EPS and sales results and issued FY22 revenue guidance above analyst estimates.

Omeros Corporation (NASDAQ:NASDAQ:OMER) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman &…

Omeros press release (OMER): Q1 GAAP EPS of -$0.53 beats by $0.08.Omeros earned royalties of $13.8M based on Rayner’s net sales of $27.7M, all of which were in the U.S., a $6.6M…

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2022, which include: On December